The OECD report highlighted a rapid rise in oncology drug approvals, from four medicines annually between 2004-2011 to 17 and 15 medicines in 2021 and 2022, respectively. 1 Despite this, inequalities ...

This is the version of the article that appears in the journal after copyediting and formatting. Note that some publishers do not allow this version to be shared and insist that the AAM be submitted.